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PENGASINGAN DAN PENILAIAN KLON cDNA SPESIFIK KEPADA 
ANTIBODI POLIKLONAL TERHADAP 12 kDa ANTIGEN REMBESAN 
PERKUMUHAN (ESA) Toxoplasma gondii 
 
 
ABSTRAK 
 
 
Toxoplasmosis adalah jangkitan zoonotik yang disebabkan oleh parasit Toxoplasma 
gondii. Ia merupakan parasit protozoa intraselular yang boleh didapati di seluruh dunia, 
dengan kekerapan yang lebih tinggi di negara-negara tropika. Walaupun risiko penyakit 
pada individu imunokompeten adalah rendah, gejala yang serius boleh berlaku apabila 
individu yang sistem imunnya terkompromi dan wanita hamil dijangkiti. Ia sangat 
mencabar lagi penting untuk menentukan sama ada jangkitan akut telah berlaku di 
kalangan wanita hamil kerana risiko jangkitan pada janin boleh menyebabkan kematian 
atau kerosakan organ yang kekal. Potensi diagnostik pelbagai antigen telah dikaji untuk 
menangani masalah ini kerana ujian diagnostik yang efisyen adalah penting untuk 
menentukan jangkitan peringkat akut. Rembesan antigen secara aktif oleh T. gondii 
yang telah didokumenkan sebagai antigen rembesan perkumuhan (ESA) didapati 
imunogenik pada kedua-dua manusia dan haiwan. Ia telah dilaporkan dapat merangsang 
tindak balas imun yang lebih baik daripada antigen parasit larut, oleh itu ESA 
merupakan  antigen yang berpotensi untuk penyelidikan.  
 
Sebelum ini, jalur 12 kDa dari ESA T. gondii telah dilaporkan sebagai penanda 
jangkitan akut dengan potensi diagnostik yang baik. ESA dihasilkan dari takizoit yang 
dituai daripada peritoneum tikus dan SDS-PAGE telah dilakukan menggunakan ESA 
tersebut. Jalur protein 12 kDa telah dikenal pasti dan dipotong, seterusnya digunakan 
 xx 
untuk menghasilkan antibodi poliklon dalam arnab. Dua jenis strategi imunisasi telah 
digunakan dalam kajian ini iaitu imunisasi menggunakan protein daripada kepingan gel 
akrilamid dan imunisasi menggunakan protein yang telah di ‘elektro-elute’ dan 
dicampurkan dengan adjuvan. Antibodi yang dihasilkan kemudiannya melalui proses 
penulenan dan dijerap dengan protein perumah E. Coli terlebih dahulu. Perpustakaan 
cDNA T. gondii Lambda ZAP II telah disaring dengan antibodi poliklon yang dijana 
dengan anti-rabbit IgG-HRP yang merupakan antibodi sekunder. Klon reaktif / positif 
telah diasingkan, diamplifikasikan dan prosedur di atas diulangi untuk langkah saringan 
yang kedua. Untuk saringan pusingan ketiga, klon yang dipilih dari saringan pusingan 
kedua telah disaring menggunakan tiga sampel serum individu yang dijangkiti 
toxoplasma dan tiga sampel serum individu yang negatif / kawalan. Antibodi anti-
manusia IgM-HRP telah digunakan sebagai antibodi sekunder. Dua klon yang 
memberikan hasil yang terbaik dari segi sensitiviti dan spesifisiti telah disaring 
seterusnya menggunakan 43 sampel serum daripada pesakit and individu sihat, dan 
antibodi sekunder yang sama digunakan. Akhirnya, dua klon terbaik diasingkan dan 
dihantar untuk penjujukan bagi menentukan rantau lengkap pengekodan DNA.  
 
Imunisasi menggunakan protein ‘elektro-eluted’ yang dicampurkan dengan adjuvan 
menghasilkan antisera bertiter tinggi iaitu 1:35, 000 manakala arnab yang diimunisasi 
dengan kepingan gel akrilamid gagal untuk menghasilkan antibodi terhadap 12 kDa 
ESA daripada T. gondii. Dua klon telah diasingkan, iaitu klon 5c dan klon 23. 
Sensitiviti dan spesifisiti klon 5c adalah 79% manakala bagi klon 23, sensitiviti adalah 
75% dan spesifisiti adalah 79%. Jika kedua-dua klon ini digabung, sensitiviti dan 
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spesifisiti sebanyak 79% diperoleh. Klon 5c telah dikenal pasti sebagai protein hipotesis 
dan klon 23 telah dikenal pasti sebagai protein hipotesis konserv.  
 
Sebagai kesimpulan, saringan perpustakaan cDNA dengan antisera poliklon arnab dan 
sera manusia telah menghasilkan dua klon cDNA yang menunjukkan sensitiviti dan 
spesifisiti yang baik untuk mengesan penyakit toksoplasmosis akut bila diuji 
menggunakan serum pesakit yang dijangkiti dengan T.gondii dan serum individu yang 
tidak dijangkiti.  
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ISOLATION AND EVALUATION OF cDNA CLONES SPECIFIC TO 
POLYCLONAL ANTIBODY AGAINST 12 kDa EXCRETORY SECRETORY 
ANTIGEN (ESA) OF Toxoplasma gondii 
 
 
ABSTRACT 
 
 
Toxoplasmosis is a zoonotic infection caused by Toxoplasma gondii. It is an obligate 
intracellular protozoan parasite distributed worldwide, with higher prevalence in the 
tropical countries.  Although the risk of an overt disease in immunocompetent 
individuals is not high, severe manifestation may result when immunocompromised 
individuals and pregnant women are infected. It is very challenging yet crucial to 
establish whether acute infection has occurred in pregnant women as the fetus could be 
at risk of infection which can cause death or permanent organ damage. The diagnostic 
potential of various antigens have been studied to address this issue as a good 
diagnostic tool is essential to determine the acute stage of the infection.  The active 
secretion of antigens by T. gondii i.e. excreted-secreted antigens (ESA) has been found 
to stimulate a better immune response than the parasite soluble antigen. Thus, ESA is a 
potential antigen for research. 
 
Previously 12 kDa band from T. gondii ESA has been determined as an acute infection 
marker with good diagnostic potential. In this study, ESA was produced from 
tachyzoites harvested from mice peritoneal exudates and subjected to SDS-PAGE. The 
12 kDa protein band was excised and used to produce polyclonal antibody in rabbits. 
Two types of immunization strategies were employed in this study namely 
immunization using protein from acrylamide gel pieces, and immunization using 
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electro-eluted protein mixed with adjuvant. The antibody produced was then purified 
and pre-adsorbed with the E. coli host proteins. The T. gondii Lambda Zap II cDNA 
library was screened with the polyclonal antibody generated with anti-rabbit IgG-HRP 
as the secondary antibody. The reactive/positive clones were cored out, amplified and 
the above procedure was repeated for secondary screening step. For tertiary screening 
step, the selected clones from secondary screening were subjected to immunoscreening 
using three toxoplasma positive serum samples and three negative/normal control 
human serum samples. Anti-human IgM-HRP was used as the secondary antibody. 
Two clones that exhibited the best results were subjected to sensitivity and specificity 
test using 43 serum samples from toxoplasma patient sera and healthy individuals, and 
the same secondary antibody. Finally, the best two clones were isolated and sent for 
sequencing to determine the complete coding region.  
 
Immunization using electro-eluted protein mixed with adjuvant produced antisera 
which produced a high titer of 1:35 000 while the rabbit immunized with acrylamide 
gel pieces failed to produce antibody against the 12 kDa ESA of T. gondii.  
Immunoscreening of the T. gondii cDNA library finally resulted in the isolation of two 
clones which showed the best immunoreactivity, namely clones 5c and 23. The 
sensitivity and specificity of clone 5c were both 79%; while for clone 23 the sensitivity 
was 75% and the specificity was 79%.  If the results of these two clones were 
combined, sensitivity and specificity of 79% was obtained. DNA sequencing identified 
clone 5c as hypothetical protein and clone 23 as conserved hypothetical protein.  
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In conclusion, immunoscreening of the T. gondii cDNA library with rabbit polyclonal 
antisera to 12 kDa T. gondii ESA had produced two cDNA clones which showed good 
sensitivity and specificity for detection of acute toxoplasmosis when tested with patient 
and healthy sera samples.  
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CHAPTER ONE  
INTRODUCTION 
 
1.1. Toxoplasmosis: Overview 
Toxoplasmosis is a cosmopolitan zoonotic infection with higher prevalence in the 
tropical countries. It is a disease caused by Toxoplasma gondii, an obligate intracellular 
protozoan parasite distributed worldwide and they have become highly adapted in order 
to invade and develop within host cells. This apicomplexan parasite is capable of 
infecting warm-blooded animals and other mammals including humans, who act as the 
intermediate hosts of the parasite. Cats and other members of the Felidae are the 
definitive hosts of this parasite. This infection which is transmitted by cats has a high 
prevalence especially at places where raw meat or undercooked meats are widely 
consumed.  
 
Toxoplasmosis can be divided into three categories; acquired toxoplasmosis, congenital 
toxoplasmosis and recrudescent/ reactivated toxoplasmosis. Acquired toxoplasmosis is 
the result of accidentally consuming food or water contaminated with cat faeces while 
congenital toxoplasmosis is when infected pregnant women pass the disease to her 
unborn child. It is assumed that one third of the world populations are infected with this 
parasite (Indra, 2003). Recurrence or reactivation of T. gondii infection is one of the 
clinical problems in congenitally infected individuals, immunocompromised hosts and 
AIDS patients (Ferguson and Dubremetz, 2007; Jackson and Hutchison, 1989). 
According to Bhopale (2003a), recrudescence of active infection could be influenced by 
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host factors such as genetic predisposition or variation in virulence among different 
strains, resulting in stage conversion back to actively proliferating tachyzoites.  
 
There are four groups of individuals in whom the diagnosis of toxoplasmosis is most 
critical namely pregnant women who acquire primary infection during gestation, fetuses 
and newborns who are congenitally infected, immunocompromised patients, and those 
with chorioretinitis. Most infections in healthy individuals are asymptomatic and self-
limiting, but these individuals remain chronically infected with presence of cysts in 
various organs especially brain. Rupture of the cysts and reactivation into serious 
disease may occur when the individuals are immunosuppressed (Dubey and Beattie, 
1988). 
 
It is apparent that toxoplasmosis is still very much a challenging subject including the 
aspect of diagnosis of the infection. Besides that, further understanding of T. gondii 
antigens can help researchers to come up with new vaccines, better prevention strategies 
and more effective treatment regimes.  
 
1.2. Toxoplasma gondii 
1.2.1. Historical perspective 
Charles Nicolle and Louis Manceaux in 1908 discovered the parasite in the lymph and 
liver of Ctenodactylus gundi, a North African rodent. It marks the beginning of the 
discovery of Toxoplasma gondii. Later in 1910, Mello reported about the same parasite 
found in sanguineous exudates and in nodules in the lung of a dog in Turin, Italy. Acute 
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toxoplasmosis described by Mello made it the first canine toxoplasmosis case to be 
reported (Miro et al., 2008). The first case of human toxoplasmosis was described by 
Janku in Czechoslovakia in 1923, who found the protozoan parasite in patients’ with 
chorioretinitis while in 1939, Wolf had successfully isolated the parasite from neonates 
with encephalitis and reported that the parasite caused congenital infection to the fetus 
(Wolf et al., 1939).  
 
First feline toxoplasmosis was not reported until 1942, although the transplacental 
transmission of the parasite was long known before that. In the 1942 study by Olafson 
and Monlux, T. gondii was identified in the lymph nodes and lungs of a cat. Only in 
1970 that the life cyle of the parasite was clearly understood and according to Levine 
(1990), several researchers from different countries found that T. gondii produces 
oocysts in the cat, and the oocysts contain two sporocysts and four sporozoites were 
found in each sporocysts. Dubey (2008) stated that in the 1980s and 1990s, several 
attempts were made to develop methods to recognize genetic differences among T. 
gondii isolates from humans and animals but only in 2005 that mapping of T. gondii 
genes was achieved. The first in-depth study of genetic variability among T. gondii 
isolates obtained worldwide by Lehmann et al. (2006) who found geographic 
differences, with some isolates being confined to Brazil whereas others were distributed 
worldwide. Until today, the search for better antigens for diagnosis and protection, and 
mechanism of disease are still ongoing. 
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1.2.2. Morphology 
The infectious stages of T. gondii can be divided into three namely the tachyzoites, 
bradyzoites, and oocysts.  
 
1.2.2.1. Tachyzoites 
The tachyzoite (figure 1.1a) is the proliferative form of the parasite that Nicolle and 
Manceaux (1908) found in the gundi. This rapidly multiplying stage of the parasite has 
also been referred to as trophozoite, the feeding form, and endozoite. They are lunate or 
crescent-shaped, measure 7 x 3 µm and can infect virtually every kind of host cell in the 
body (Ferguson and Dubremetz, 2007), phagocytic and non-phagocytic, and also 
nucleated cells by active penetration but not the non-nucleated red blood cells (Waree, 
2008). Multiplication occurs through a specialized process that was first described by 
Goldman et al., (1958) called endodyogeny. Endodyogeny is a process during which 
two progeny form within the parent parasite (Wong and Remington, 1993). The 
disrupted host cells will disseminate tachyzoites to the bloodstream and this causes a 
strong inflammatory response and infection of the tissues including eye, skeletal and 
heart muscle as a result of its repeated replication. The rapid invasion of the parasite 
into the host cells and neighbouring cells suggest that they probably have a secretory 
function that helps them to enter the host cell (Nichols et al., 1983). As the immune 
response of the host cell take charge as a result of an infection, the tachyzoites are 
transformed into bradyzoites to form cysts (Montoya and Liesenfeld, 2004).  
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1.2.2.2. Bradyzoites 
Bradyzoites (figure 1.1b) or life-long tissue cysts are slow dividing form of the parasite 
and they persist in latent infection for the life of the host. Cysts are the infective stage 
for intermediate and definitive hosts. The tissue cysts vary in size; young tissue cysts 
may be as small as 5 μm in diameter and contain only two bradyzoites, while older ones 
may contain thousands of organisms, and this could explain why the bradyzoite is the 
only stage that can initiate the sexual phase (Dubey, 2010). This tissue cysts containing 
hundreds and thousands of bradyzoites form may develop in visceral organs, including 
the lungs, liver, and kidneys, they are more prevalent in the neural and muscular tissues, 
including the brain, eyes, and skeletal and cardiac muscles (Dubey, 2010). The encysted 
bradyzoites do not cause any harm but if the cysts rupture and bradyzoites are released 
from the cysts, they can transform back into tachyzoites and cause recrudescence of 
infection especially in immunocompromised patients (Montoya and Liesenfeld, 2004).  
 
1.2.2.3. Oocysts 
Cats are the definitive host for T.  gondii and oocysts are normally shed in cat faeces 
after the completion of sexual phase in the feline gut epithelium. The oocysts (figure 
1.1c) excreted are unsporulated and non-infectious, but it can become infectious after 48 
hours or more of environmental incubation (Miro et al., 2008). As a result of 
environmental incubation, sporulation of the oocysts take place which give rise to 
sporocyst containing sporozoites, and when ingested by mammals (including man), they 
will become infected (Montoya and Liesenfeld, 2004).  
  
 6 
 
 
Figure 1.1a: The tachyzoites, which are the invasive form of the T. gondii parasite. 
Scale bar = 10 µm. (http://www.sciencedirect.com/science/article/pii/S0166685101003140) 
 
 
 
Figure 1.1b: The bradyzoite stage or the encysted form of T. gondii 
(http://parasitology1000.blog.com/educationalimages/) 
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Figure 1.1c shows F. Unsporulated oocyst in fecal float of cat feces. G. Sporulated 
oocyst with a thin oocyst wall (large arrow), 2 sporocysts (arrowheads). Each sporocyst 
has 4 sporozoites (small arrow) which are not in complete focus. Scale bar = 10 µm. 
(http://www.ars.usda.gov/main/docs.htm?docid=11013) 
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1.2.3. Life cycle 
The life cycle of T. gondii can be divided into two phases; the sexual phase that occurs 
exclusively in feline, the definitive host and the asexual phase that takes place in 
mammals or intermediate hosts. The sexual phase or entero-epithelial cycle is initiated 
after ingestion of an infected prey or faeces contaminated with infected sporocysts 
(figure 1.2). A typical process of gamete formation and fusion will then take place in 
the cat gut epithelium giving rise to a zygote. The zygote will eventually develop into 
immature oocysts and will be shed in cat faeces. Depending on the environmental 
temperature and humidity, the oocysts will mature into resistant sporulated oocysts 
(sporocysts) containing sporozoites. At this stage, the oocysts have become highly 
infectious and accidental consumption by other cats will result in initiation of a new 
sexual cycle. But if ingested by any warm blooded animal, asexual cycle will then take 
place.   
 
The asexual cycle consists of two stages, depending on whether the infection is in acute 
or chronic phase. Once in the intermediate hosts, the sporozoites will be released in the 
intestinal lumen and undergo endodyogeny. They will differentiate into the rapidly 
dividing tachyzoite and invade different cells during the acute phase. They replicate 
inside a cell, and when tachyzoites are accumulated in the cell, the cell rupture and they 
exit the cell to infect the neighboring cells. As the host's immune response rises to the 
challenge, tachyzoites differentiate into bradyzoites and form tissue cysts that are very 
stable and infectious if tissue from the animal is eaten. The cysts are predominantly  
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Figure 1.2: Summary of complete life cycle of Toxoplasma gondii. 
(http://www.microbeworld.org/images/stories/twip/t_gondii_cycle.jpg) 
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found in the central nervous system and muscle tissue, and may reside for life of the 
host (Black and Boothroyd, 2000). 
 
As they pass through the digestive tract, the ingested cysts are ruptured causing the 
release of the bradyzoites. These bradyzoites are capable of differentiating back to the 
proliferative tachyzoite stage and will be dispersed throughout the body, thereby 
completing the asexual phase (Black and Boothroyd, 2000). More often than not the 
immune response will effectively prevent the spreading of the tachyzoites. However, 
such reactivation may go unimpeded in immunocompromised patients, resulting in a 
massive and potentially fatal infection.  
 
1.2.4. T. gondii strains 
There is more than one strain of T. gondii and there are evidences of marked differences 
between the strains (Bhopale, 2003b). Virulence of a strain is determined on the basis of 
its ability to kill the white mice (Thomas, 1979) and different strains of Toxoplasma 
vary in their virulence. The strains have three clonal lineages designated type I, II and 
III which differ in virulence and epidemiological pattern of occurrence. Type I and type 
II are virulent strains while type III is avirulent. Strains isolated from animals are 
mostly type III while type I and type II strains have been recorded in patients with 
congenital disease and AIDS (Montoya and Liesenfeld, 2004). Various techniques like 
immunoprecipitation, Western blot, isoenzyme analysis as well as molecular genetic 
techniques have been employed to demonstrate the strain-specific differences of T. 
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gondii isolates and all the informations revealed that there is more than one T. gondii 
strain among isolates in the nature with difference in virulence (Bhopale, 2003b). 
 
1.3. Epidemiology 
T. gondii is distributed world-wide but the frequency of infection in man and animals 
varies from country to country. The disease is one of the most important infectious 
diseases causing epidemiological and clinical impacts in humans. The prevalence rate of 
infection is greater in the tropics and subtropics than in colder regions. Predisposing 
factors like direct contact with cats and consumption of undercooked meat play a 
crucial role in Toxoplasma infection. Lones et al. (2001) reported that the United States 
has low T. gondii seroprevalence compared to France and Latin America or sub-
Saharan Africa. They indicated that a significant proportion of toxoplasmosis in the 
United States may be due to ingestion of raw or undercooked infected meat or cross-
contamination from such meat. Ancelle et al. (1996) also related the higher 
seroprevalence of T. gondii in France to the common consumption of undercooked 
meat.  
 
Evidence of Toxoplasma infection in man and in a number of domestic and wild 
animals had been shown in serological surveys in Malaysia and Singapore (Thomas, 
1979). High prevalence was recorded among the Malaysian population and the highest 
seroprevalence of toxoplasmosis in most of the studies was in Malays, followed by 
Indians, Orang Asli (aborigines) and Chinese (Nissapatorn and Abdullah, 2004). The 
highest prevalence rate among Malays may indicate that oocysts from cats are the main 
source of infection. This study is supported by other studies in this region (Partono and 
 12 
Cross, 1975; Gandahusada, 1978; Wong et al, 2000). Various groups of population have 
been studied and the presence of specific antibodies were demonstrated in people of 
both sexes in all age groups including neonatals, infants, children and adults of all races. 
However, the prevalence rate was highest among children below 10 years of age 
indicating possible infection with oocysts from contaminated soil rather than from 
contaminated meat (Thomas, 1979).  
 
1.4. Transmission 
There are various ways that T. gondii can be transmitted since cats are everywhere 
except the frozen arctic. It could be transmitted at any stage of its life cycle and to 
humans and animals. The transmission could occur congenitally, from mother to the 
fetus, carnivorism, through fecal oral route and other less common route of infection 
like transplantation and laboratory accidents (figure 1.3).  
 
1.4.1. Congenital 
Wolf et al. (1939) first described congenital T. gondii infection in a human child and 
later found that it occur in many species of animals as well, particularly sheep, goats, 
and rodents (Dubey, 2008). The differing risk factors and modes of transmission could 
probably explain the significant divergence on the prevalence and incidence of 
toxoplasma infection among pregnant women between countries (Hall et al., 2001). The 
birth prevalence of congenital toxoplasmosis ranges from one to ten per 10, 000 live 
births (Lebech et al., 1999) where in the majority of cases the infection is either  
 13 
 
 
Figure 1.3: Transmission of T.gondii to humans and animals. 
(http://www.medscape.com/viewarticle/462440_2) 
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asymptomatic or symptoms may pass unnoticed. As can be seen from figure 1.4, the 
frequency of transmission varies considerably according to the time during gestation 
that the mother became infected and is inversely related to severity of the disease 
(Montoya and Lisenfeld, 2004).  
 
The parasite enters the fetal circulation by infection of the placenta and if it happens in 
early pregnancies, it may result in death and spontaneous abortion. However, infection 
during late pregnancies usually results in normal appearing newborns where infection 
initially goes unnoticed but some complications of the disease may develop later in life 
(Remington et al., 2001). The rate of transmission rises to 30–50 percent in women 
infected in the second trimester, and 60–70 percent for those infected during the third 
trimester.  It is therefore generally accepted that there is no significant risk of congenital 
infection in the fetus when infection occurs before conception (Health protection 
agency, 2010). 
 
1.4.2. Carnivorism 
There is increasing evidence that the ingestion of cysts in meat is a common method of 
transmission of T. gondii. In 1954, Weinman and Chandler suggested that transmission 
might occur through the ingestion of undercooked meat while Jacobs et al. (1960) 
provided evidence to support this idea. They found out that the cysts wall was 
immediately dissolved by proteolytic enzymes of T. gondii but the released bradyzoites 
remain intact. Desmonts et al. (1965) illustrated the importance of carnivorism in  
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Figure 1.4: The frequency of transplacental transmission of toxoplasmosis from mother 
to fetus by trimester and its relation to the severity of infection on fetus. 
(http://www.obgyn.net/english/pubs/features/presentations/OB_toxoplasmosis_pregnan
cy-Agrawal/OB_toxoplasmosis_pregnancy.ppt) 
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transmission of T. gondii by proving that the prevalence of T. gondii is much higher in 
sheep than in horses or cattle. Dubey (2008) highlighted that it is common in humans in 
some vicinities where raw meat is consumed regularly. The ability of cysts to survive 
gastric juice and incidence of toxoplasma which is common in swine, sheep, cattle and 
other animals (Jacobs et al., 1960) appear to illustrate the carnivorism transmission of 
the parasite. Durfee and Chien (1971) reported the serial transmission of toxoplasma 
from mouse to pig to cat, and back to mouse.  
 
1.4.3. Fecal oral 
The high incidence of toxoplasma infection in vegetarians and herbivores cannot be 
explained by congenital and carnivorism transmission. T. gondii infectivity associated 
with cat feces was initially discovered by Hutchinson (1965) and was considered as a 
breakthrough because, until then, both known forms of T. gondii (tachyzoites and 
bradyzoites) were killed by water. Cats can shed millions of oocysts after ingesting only 
one bradyzoite, indicating the important role of oocysts excreted by infected cats that 
attributes to epidemics of toxoplasmosis in human beings and sheep (Teutsch et al., 
1979). Sheep could readily acquire infection because they are known to graze closely to  
the ground (Quinn and McGraw, 1972). T. gondii oocysts could also contaminate water 
as several outbreaks of toxoplasmosis in humans have been linked epidemiologically to 
drinking of unfiltered water (Bowie et al., 1997). 
 
1.4.4. Other routes 
Congenital, carnivorism and fecal-oral transmission are the most common routes of 
transmission of T. gondii. There are some other ways that toxoplasma can be 
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transmitted, though they are less common or very rare. Organ transplantation and blood 
transfusion are two extraordinary methods of spread in man. Reynolds et al. (1966) 
reported that a patient with chronic renal disease who was placed in an 
immunosuppressive regimen died of acute disseminated toxoplasmosis one month after 
receiving a renal transplant. The cause of death was identified from serologic studies 
and it suggested that primary infection with T. gondii occurred at the time of 
transplantation. Raisanen (1977) studied the transmission of Toxoplasma via blood 
transfusion using laboratory rabbits. Human blood was inoculated with toxoplasma 
organisms and stored for 28 days before being injected into the ear vein of the rabbits. 
The test rabbits developed toxoplasmosis and similar result were obtained by 
transfusing rabbits with blood obtained from rabbits subcutaneously injected with 
toxoplasma organisms. Herwaldt and Juranek in their review of laboratory-acquired 
parasitic infections in 1993 reported that needlestick injuries due to carelessness were 
the most common laboratory accident that contributes to the infection.  
 
1.5. Toxoplasma infection 
1.5.1. Infection in animals 
T. gondii is one of the most ubiquitous organisms and several reports of fatal 
toxoplamosis infection in animals are available in the literature. Exposure to the 
organism and infection by it are common but the clinical signs of toxoplasmosis vary 
considerably with the species affected and very likely with the strain of organism 
involved (Quinn and McGraw, 1972). According to Lindsay et al. (1997), there is no 
toxoplasmosis in areas where there are no cats until Prestud et al. (2007) reported other 
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possible sources of infection due to T. gondii in the Arctic. The first animal 
toxoplasmosis reported was canine toxoplasmosis in Italy in 1910 and over the next 30 
years, canine toxoplasmosis was reported in a few other countries (Dubey and Beattie, 
1988).  
 
Toxoplasmosis in farm animals like sheep and goats deserves special attention because 
of their economic impact. According to Dubey and Beattie (1988), T. gondii infected 
goats acquire the disease through contaminated food and water from infected cat faeces 
and concluded that toxoplasmosis in these animals was significantly associated with the 
presence of cats roaming in the farms. Fetal infection, abortion and neonatal loss can 
occur if the parasite is encountered during pregnancy thus explaining its major role in 
economical impact upon their farming. Levine (1990) described that toxoplasma appear 
to be less common in cattle than sheep and Dubey (2003) supported the fact by proving 
that cattle and horses are resistant to clinical T. gondi. It is even capable of infecting 
marine lives as Cole et al. (2000) isolated viable T. gondii from sea otters in the United 
States and since then, many reports of fatal toxoplasmosis in marine mammals have 
been published. 
 
1.5.2. Entry into host cell 
Since T. gondii is an obligate intracellular parasite, it requires an appropriate host cell 
for its replication. T. gondii is capable of invading and establishing productive infection 
in both phagocytic and non-phagocytic cells through active invasion. It is termed the 
active invasion because the entry mechanism is largely driven by the parasite itself and 
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has been observed in many different cell types (Sibley et al., 1985). In order to invade 
the cell, the parasite will recognize an attachment site (Figure 1.5) and attach to the 
target cell. Upon entry into the host cell, the parasite will look for an appropriate point 
of attachment and forcibly penetrates the host cell through an anular junction formed 
between them (Bhopale, 2003a). Modifications of the cell membrane as a result of the 
parasite penetration give rise to the parasitophorous vacuole, a specialized compartment 
in which the parasite resides. Replication of the parasite will not take place in the 
vacuole, instead new vacuole will be formed and the parasite will exit into the new 
vacuole where replication takes place (Speer et al., 1995). In the presence of 
complement, extracellular tachyzoites will be killed by specific antibody.  
 
1.5.3. Host parasite interaction 
T. gondii may possess organelles that are required for independent existence; however, 
intracellular environment of a host is required for its growth and replication (Wong and 
Remington, 1993).  T. gondii usually parasitizes both definitive and intermediate hosts 
but severe clinical manifestations occur very rarely. The spread of T. gondii to 
mesenteric lymph nodes and to distant organs could be fatal to the host as they are at 
high risk of intestinal necrosis and severe organ damage (Schreiner and Liesenfeld, 
2009). Necrosis is caused by the intracellular growth of tachyzoites since all stages of 
the parasite contain functional mitochondria. According to Pfefferkorn (1990), this is 
how the parasite produces energy to support its growth. Inflammation usually follows 
the initial necrosis. By about the third week after infection, tachyzoites may localize as  
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Figure 1.5: The process of parasitophorous vacuole formation and the endodyogeny 
that take place during asexual cycle of the parasite. 
(http://www.charite.de/sysbio/research/toxoplasma/) 
 
          PV: Parasitophorous vacuole 
         ER: Endoplasmic reticulum 
                                                                                    M: Mitochondrion 
 
 
 
 
Parasite 
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tissue cysts in neural and muscular tissues as it begin to disappear from visceral tissues. 
Since immunity is less effective in neural organs, tachyzoites persist longer in the spinal 
cord and brain than in visceral tissues, although this varies with the strain of T. gondii 
and the host species (Dubey, 2010). 
 
1.5.4. Mode of infection and pathogenesis 
Humans, who are the intermediate host for T. gondii are generally infected by ingestion 
of oocysts released in cat faeces or by consuming undercooked meat from infected 
animals. Depending on factors like age of the host and the organs involved, the response 
of the host to the infection varies (Quinn and McGraw, 1972). Following ingestion, 
enzymatic degradation of the outer wall of the cysts will occur and bradyzoites and 
sporozoites are released into intestinal lumen. There they undergo rapid invasion and 
multiplication where they become tachyzoites, disseminating through the lymphatic 
system to different organs inside the host. Intracellular growth of the parasite will lead 
to apoptosis and cell necrosis surrounded by an acute inflammatory response (Miro et 
al., 2008). Often, necrosis is the only response observed in tissues of organisms, 
especially for acute cases. Virulent parasites can destroy host cells in 24 to 48 hours 
(Bommer, 1969).At this point, the parasite can be excreted through different biological 
fluids but these tachyzoites are very labile and are easily destroyed which makes 
transmission to other hosts very unlikely.  
 
According to Feldmen (1968), the rapid multiplication of the parasite in fetus and young 
children can cause severe outcomes. If the parasite invades the liver and spleen, areas of 
 22 
focal necrosis may be formed and could cause hepatosplenomegaly and sometimes 
jaundice in the neonate. Retinochoroiditis, hydrocephaly and microcephaly as well as 
cerebral calcification may be present. Both fatal and self-limited encephalitis with 
lymphadenopathy have been described in young children. However, severe 
inflammatory reactions are less common in adults (Christie, 1969) and the spread of the 
infection is rarely fatal (Jacobs, 1970). 
 
Appearance of IgA antibodies indicate the sub-acute phase of the disease. This IgA 
which is specific for T. gondii enteroepithelial stages eliminates tachyzoite replication 
in the intestinal phase but not those localized in the nervous system. The chronic form 
of the disease is characterized by the disappearance of tachyzoites from visceral tissues 
whereby bradyzoites persist within cysts. This phase, which inhibits tachyzoites 
proliferation in blood and tissues, is long-lasting and is associated with a systemic 
immune response (Montoya and Liesenfeld, 2004). One of the most common causes of 
CNS complications is reactivation of latent infection in immunocompromised patients 
such as AIDS (Luft and Remington, 1992). 
 
1.5.5. Immune response 
T. gondii is a highly successful pathogen as it is able to evade the immune system 
mechanism of the host.  When tachyzoites are disseminated to the organs in the human 
body, both cellular and the humoral immune responses control the infection, but the 
type I cell-mediated immunity plays a key role in the host resistance to T. gondii 
infection (Hou et al., 2011). The antibodies produced during humoral immune response 
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are important for diagnosis of toxoplasmosis in human as they have been found to be 
able to kill the extracellular T. gondii by restricting the multiplication of the parasite. 
The parasite will be lysed in the presence of the complement. The main cells of defense 
against the parasite are the macrophages and NK cells, in which the macrophages 
produce cytokine together with dendritic cells during the acute phase of infection 
(Waree, 2008).  
 
The cytokines that are involved in the immune process against T. gondii infection 
include IL-2, IL-12, IFN-γ, TNF-α, and IL-6. IFN-γ activates the macrophages and 
hydrogen peroxide that kills the parasites will be released. However, a recent finding 
suggested that they inhibit the function of macrophage by inducing rapid activation of 
transcription factors (Buzoni-Gatel and Werts, 2006). By blocking the nuclear 
translocation of both factors and preventing macrophages from producing IL-12 or 
TNF-α, the parasite is able to evade or subvert the immune response of its host. In 
immunocompetent hosts, the tissue cysts are able to persist for several years after 
infection, most of the time as long as the life of the host and the immunity does not 
eliminate an established infection.  
 
1.6. Clinical Presentation/ Characteristics 
The clinical manifestation of T. gondii infection can go unnoticed or asymptomatic. 
Depending on the immune status of the patient and the clinical setting, the signs and 
symptoms of infection vary. For instance, different clinical presentations have been 
observed in immunocompetent adults and children, immunocompromised patients with 
and without AIDS, congenital toxoplasmosis and ocular toxoplasmosis.  
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1.6.1. Immunocompetent adults and children 
Aquired acute toxoplasmosis infection in immunocompetent adults (including pregnant 
women) and children often manifests as asymptomatic disease and only about 10% of 
individuals acutely infected with T. gondii present with a short, self-limiting and non-
specific illnesses that rarely need treatment (Montoya and Liesenfeld, 2004). The most 
common clinical presentation is cervical lymphadenopathy, where the lymph nodes 
measure only a few centimeters in diameter (McCabe et al., 1987). Toxoplasmosis may 
account for 5 percent of clinically significant lymphadenopathy cases (McCabe et al., 
1987) and very infrequently, pneumonitis, myocarditis, hepatitis, polymyositis, 
encephalitis and fever of unknown origin can arise in apparently immunocompetent 
individuals (Montoya and Liesenfeld, 2004). Acute toxoplasma infection in pregnant 
women does not differ from T. gondii infection in other immunocompetent individuals. 
Although cervical lymphadenopathy may seem likely, the infection is most commonly 
asymptomatic. Due to the asymptomatic course, the disease may be transmitted to the 
fetus unknowingly (Petersen and Liesenfeld, 2007). 
 
1.6.2. Immunocompromised patients with and without AIDS 
Immunocompromised patients are not as fortunate as immunocompetent individuals 
when it comes to T. gondii infection as the disease can be life-threatening in 
immunocompromised individuals (Liesenfeld et al., 1999). This is because these 
individuals are at high risk of reactivation of chronic or latent infection following 
rupture of cysts in the central nervous system (Porter and Sande, 1992).  Liesenfeld et 
al. (1999) reported that patients with reactivated toxoplasmosis often present with signs 
